Drug Trial Radar · NCT00327691
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
Last checked: Nov 19, 2026Latest source record: May 3, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,600
Actual
Start
Apr 1998
Primary completion
Not stated
Study completion Aug 2004
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 35 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.
Conditions
- Cardiovascular Disease
- Cerebrovascular Accident
- Coronary Heart Disease
Interventions
AtorvastatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome is the time to occurrence of a major
- cardiovascular event, defined as the composite outcome of the
- following clinical endpoints
- CHD death
- Non-fatal/Non-procedure related MI
- Resuscitated cardiac arrest or fatal/non-fatal stroke
Locations
314 sites in 14 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Alabaster, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Hoover, Alabama
Pfizer Investigational Site
Montgomery, Alabama
Pfizer Investigational Site
Mesa, Arizona
Pfizer Investigational Site
Mesa, Arizona
Pfizer Investigational Site
Burbank, California
Pfizer Investigational Site
Camp Pendleton, California
Pfizer Investigational Site
Fresno, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
Loma Linda, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Modesto, California
Pfizer Investigational Site
Pasadena, California
Pfizer Investigational Site
Rancho Mirage, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Santa Rosa, California
Pfizer Investigational Site
Stanford, California
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Denver, Colorado
Pfizer Investigational Site
Bridgeport, Connecticut
Pfizer Investigational Site
Hartford, Connecticut
Pfizer Investigational Site
New Britain, Connecticut
Pfizer Investigational Site
Newark, Delaware
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Gainsville, Florida
Pfizer Investigational Site
Gainsville, Florida
Pfizer Investigational Site
Hollywood, Florida
Pfizer Investigational Site
Inverness, Florida
Pfizer Investigational Site
Lakeland, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Showing 40 of 314 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.